Acasti Pharma Inc reports results for the quarter ended in March - Earnings Summary

Grace Therapeutics

23/06/2023 17:48

* Acasti Pharma Inc  ACST.OQ  reported a quarterly adjusted
loss
of 65 cents​​ per share for the quarter ended in March. The lone
analyst forecast for the quarter was for a loss of 14 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Acasti Pharma Inc's reported EPS for the quarter was a
loss
of 65 cents​.
    * The mean earnings estimate of analysts had risen by
about 12% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Acasti Pharma Inc shares had risen by 23.9% this
quarter and
gained 13.7% so far this year.
    * The company reported a quarterly loss of C$29.09 million.
    * Wall Street's median 12-month price target for Acasti
Pharma Inc
is $2.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data June
23 at 04:47 p.m. UTC. ​All figures in Canadian dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.14          -0.65          Missed
 Dec. 31 2022      -0.15          -0.09          Beat